Replimune Group, Inc. (REPL) - 10-Q Summary
Business Context and Reporting Period
Company: Replimune Group, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Replimune is a commercial-stage biotechnology company focused on oncolytic immunotherapies. The company's lead product, TUDRIQEV (vusolimogene oderparepvec-wtpg), received FDA accelerated approval in August 2026 (post-period) for the treatment of advanced cutaneous melanoma in combination with nivolumab. The company operates as a single segment and has incurred recurring losses since inception.
Key Financial Metrics
| Metric (in thousands, except per share) | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(69,766) | $(86,693) |
| Net Loss Per Share (Basic & Diluted) | $(0.72) | $(0.95) |
| Operating Expenses | $68,247 | $90,422 |
| Research & Development (R&D) | $49,277 | $57,843 |
| Selling, General & Administrative (SG&A) | $18,970 | $32,579 |
| Cash & Cash Equivalents | $185,359 | $104,275 (Q1 2026) |
| Short-term Investments | $9,969 | $59,865 (Q1 2026) |
| Total Liquidity (Cash + ST Inv) | $195,328 | $164,140 (Q1 2026) |
| Long-term Debt (Net) | $84,114 | $83,308 (Q1 2026) |
| Accumulated Deficit | $(1,332,285) | $(1,262,519) (Q1 2026) |
Note: Revenue was $0 as the product received FDA approval in August 2026, subsequent to the reporting period.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $16.9 million (19.5%) year-over-year, driven primarily by a $22.2 million reduction in total operating expenses.
- Expense Reductions:
- R&D: Decreased $8.6 million, largely due to a $7.6 million drop in unallocated expenses (personnel and consulting) following a restructuring in April 2026. Direct costs for the IGNYTE, ARTACUS, and CERPASS studies declined as enrollment completed or wound down, partially offset by increased spending on the IGNYTE-3 confirmatory trial and the RP2 REVEAL study.
- SG&A: Decreased $13.6 million, primarily due to a $10.2 million reduction in external sales/marketing costs and a $3.4 million decrease in personnel costs following a 55% reduction in the commercial team.
- Other Income/Expense: Total other expense increased by $5.2 million (from income of $3.7M to expense of $1.5M). This was driven by a $2.8 million decrease in investment income due to lower investment balances and a $1.3 million increase in foreign currency transaction losses.
- Liquidity: Cash and short-term investments decreased by approximately $78.8 million from the beginning of the quarter (March 31, 2026) to June 30, 2026, primarily due to operating cash outflows.
Guidance, Outlook, and Risks
- Subsequent Events (Post-Period):
- FDA Approval: On August 6, 2026, the FDA granted accelerated approval for TUDRIQEV in combination with nivolumab for advanced melanoma. Commercial launch is in progress.
- Capital Raise: On August 10, 2026, the company completed an equity offering raising approximately $141.0 million in net proceeds.
- Liquidity Outlook: Management expects that existing cash, short-term investments, and the proceeds from the August 2026 offering will be sufficient to fund operations for greater than twelve months from the issuance of the financial statements.
- Key Risks:
- Accelerated Approval Contingency: Continued approval of TUDRIQEV is contingent on verification of clinical benefit in confirmatory trials, specifically the ongoing IGNYTE-3 Phase 3 trial. Failure to confirm benefit could result in withdrawal of approval.
- Commercialization: The company has no prior experience commercializing a product. Success depends on establishing sales infrastructure, reimbursement, and market acceptance.
- Legal Proceedings: The company is defending a class action lawsuit and derivative actions related to FDA Complete Response Letters (CRLs) issued in 2025 and 2026. The SEC concluded its investigation in June 2026 without recommending enforcement action.
- Debt Covenants: The company has a $200 million term loan facility with Hercules Capital. Covenants require maintaining specific cash balances or achieving revenue/market cap thresholds. The maturity date was extended to October 2029 following FDA approval.
Investor Verification Checklist
- Confirmatory Trial Status: Verify enrollment progress and interim data for the IGNYTE-3 Phase 3 trial, which is required to maintain TUDRIQEV's accelerated approval.
- Commercial Infrastructure: Assess the company's ability to rebuild its sales and marketing team following the 55% reduction in the commercial workforce.
- Reimbursement Landscape: Monitor payer coverage decisions and pricing negotiations for TUDRIQEV in combination with nivolumab.
- Debt Compliance: Review compliance with Hercules Capital covenants, specifically the requirement to maintain unrestricted cash or achieve revenue/market cap targets.
- Legal Exposure: Track the status of the pending class action lawsuit (Jboor v. Replimune) and any potential settlement costs.